| ISPC 0.1365 17.17% | CTNT 0.0953 -40.73% | BYND 0.8226 5.19% | YXT 0.496 34.05% | TZA 5.08 -6.45% | EFOI 6.49 210.53% | TSLL 13.9 6.35% | NVDA 201.68 1.68% | BITO 10.63 2.71% | NFLX 97.31 -9.72% | INTC 68.5 0.00% | ZSPC 0.0536 -38.46% | TQQQ 58.59 3.83% | SOXS 18.87 -6.95% | TSLA 400.62 3.01% | XLE 55.02 -2.76% | AMC 1.86 15.53% | SCO 8.47 9.72% | PLUG 2.78 -2.80% | BMNG 1.6 4.58% | IBIT 43.94 2.83% | AAL 12.78 4.16% | BZAI 2.52 45.66% | CRML 12.56 35.49% | SOFI 19.43 2.10% | HIVE 2.51 14.87% | GRAB 4.21 4.73% | SPY 710.14 1.21% | SQQQ 56.39 -3.79% | SOXL 94.68 7.14% | SMR 12.65 10.87% | BMNR 22.95 2.27% | SNAP 6.03 0.17% | UCAR 1.49 29.57% | HIMS 28.82 6.78% | LZMH 0.1736 -84.07% | HYG 80.65 0.37% | DRIP 5.25 9.83% | ONDS 10 -1.96% | DVLT 0.758 -9.49% | AAPL 270.23 2.59% | QQQ 648.85 1.31% | MARA 11.6 0.43% | MSTR 166.52 11.80% | AMZN 250.56 0.34% | PLTR 146.39 2.54% | SPDN 9.13 -1.19% | PBM 7.6 29.47% | IONQ 46.09 3.16% | MSFT 422.79 0.60%

LifeVantage Corporation (NASDAQ: LFVN) Q4 Earnings Overview

LifeVantage Corporation (NASDAQ: LFVN) is a health and wellness company known for its focus on nutritional supplements and skincare products. The company operates globally, with significant markets in the Americas, Asia/Pacific, and Europe. LifeVantage competes with other health and wellness companies, striving to maintain its market position through innovative products and strategic growth.

On September 4, 2025, LifeVantage reported its Q4 earnings, revealing an earnings per share (EPS) of $0.14, which fell short of the expected $0.17. Despite this, the company showed a year-over-year improvement, with net income per diluted share rising to $0.15 from $0.10. Adjusted earnings per diluted share also increased to $0.17 from $0.14, indicating some positive financial momentum.

The company's revenue for the fourth quarter was $55.1 million, below the anticipated $57.9 million. However, this still represented a 12.6% increase from the previous year. In the Americas, revenue grew by 14.1%, while Asia/Pacific and Europe saw a 7.6% increase. Excluding foreign currency impacts, the growth in Asia/Pacific and Europe was 1.6%, highlighting regional performance variations.

LifeVantage's financial metrics provide further insight into its market position. The company has a price-to-earnings (P/E) ratio of 15.22 and a price-to-sales ratio of 0.67, indicating how the market values its earnings and revenue. The enterprise value to sales ratio is 0.62, suggesting a slightly lower valuation when accounting for debt and cash.

The company's financial health is supported by a debt-to-equity ratio of 0.36, reflecting moderate debt levels. With a current ratio of 1.66, LifeVantage demonstrates strong liquidity, ensuring it can meet short-term liabilities. The earnings yield of 6.57% offers insight into the earnings generated per dollar invested, showcasing the company's profitability.

Published on: September 5, 2025